{"prompt": "['5.2.2.2 Management of Potential Adverse Events Associated with Lenvatinib', '5.2.2.2.1 Management of Hypertension', 'Hypertension is a potential adverse event when using any drug active against the VEGF', 'pathway, including lenvatinib. To minimize the need for lenvatinib dose interruptions and', 'reduction, a blood pressure of VI 150/90 is required at the time of enrollment and subjects known', 'to be hypertensive should be on a stable dose of antihypertensive therapy for at least 1 week', 'before receiving Cycle 1 Day 1. The management of hypertension occurring during trial is', 'outlined below in Table 5.', 'Table 4. Recommendations for management of hypertension during trial', 'Blood pressure level', 'Management', 'Systolic BP >140 mmHg up to 160 mmHg or diastolic', 'Continue lenvatinib and institute antihypertensive', 'BP >90 mmHg up to 100 mmHga,b', 'therapy for subjects not already receiving', 'antihypertensive', 'OR', 'For those subjects already on antihypertensive', 'medication, dose of the current agent may be increased,', 'if appropriate, or 1 or more agents of a different class', 'of antihypertensive should be addedc,', 'Systolic BP >160 mmHg or diastolic mmHg', 'Continue lenvatinib and institute antihypertensive', 'and not on optimal antihypertensive therapy', 'therapy for subjects not already receiving', 'antihypertensive', 'OR', 'For those subjects already on antihypertensive', 'medication, dose of the current agent may be increased,', 'if appropriate, or 1 or more agents of a different class', 'of antihypertensive should be addedc,d', 'Systolic BP >160 mmHg or diastolic BP >100 mmHg', '1. Withhold lenvatinib', 'despite optimal antihypertensive therapy', '2. When systolic BP <150 mmHg, diastolic BP <95', 'mmHg, and patient has been on a stable dose of', 'antihypertensive therapy for at least 48 hours, resume', 'lenvatinib at reduced dosee', 'Life-threatening consequences (malignant', 'Urgent intervention is indicated. Discontinue lenvatinib', 'hypertension, neurological deficit, or hypertensive', 'and institute appropriate medical management.', 'crisis)', 'a. Confirmed on 2 assessments a minimum of 1 hour apart', 'b. One BP assessment is defined as the mean value of 3 measurements at least 5 minutes apart', \"c. Choice of antihypertensive treatment should be individualized to the subjects' clinical circumstances and follow standard medical practice.\", 'd. For subjects with hypertension and proteinuria, management with an angiotensin-converting enzyme inhibitor or angiotensin-Il receptor', 'antagonist is preferred [35]', 'e. During the treatment period, subjects with systolic BP >160 mm Hg or diastolic BP 100 mm Hg must have their BP monitored every 2', 'weeks or more frequently as clinically indicated until systolic BP has been 150 mm Hg and diastolic BP has been <95 mm Hg for 3', 'Page 19', 'Version Date: 02/09/2020']['consecutive months. If a repeat event of systolic BP >160 mm Hg or diastolic BP >100 mm Hg occurs, the subject must resume evaluation', 'every 2 weeks until systolic BP has been 150 mm Hg and diastolic BP has been 95 mm Hg for 3 consecutive months.', 'BP = blood pressure', '5.2.2.2.2 Management of Proteinuria', 'Proteinuria has been reported in patients receiving lenvatinib. Regular assessment of proteinuria', 'should be conducted as detailed in the Trial Flow Chart (Section 6.0) and as clinically indicated.', 'Guidelines for the assessment and management of proteinuria:', '1. If urine dipstick of \">2+ proteinuria is detected, a 24-hour urine collection should be', 'completed within 72 hours for protein quantitation in the following situations:', 'The initial occurrence of >2+ proteinuria on urine dipstick while receiving lenvatinib', 'A subsequent increase in severity of urine dipstick proteinuria occurring on the same', 'lenvatinib dose level', 'When there has been a lenvatinib dose reduction and at the new dose level the urine', 'protein dipstick result is >2+', '2. Grading of proteinuria will be performed according to CTCAE 4.0 (Appendix 2) and', 'based on the 24-hour urine collection for total protein if available from that time point.', '3. Urine dipstick testing for subjects with proteinuria >2+ should be performed every 2', 'weeks or more frequently as clinically indicated until the results have been 1+ or negative', 'for 3 consecutive months.', '4. Management of lenvatinib administration will be based on the grade of proteinuria', 'according to instructions contained in Table 3 (Dose Modifications for Lenvatinib', 'Treatment-Related Toxicity).', '5.2.2.2.3 Management of QT interval prolongation', 'The effect of a single 32 mg dose of lenvatinib on the QT/QTc interval was evaluated in a', 'thorough QT study in healthy subjects (E7080-A001-002) In this study lenvatinib did not', 'prolong the QT/QTc interval. QT/QTc interval prolongation has been reported at a higher rate in', 'patients treated with lenvatinib. Monitor ECG in patients with congenital long QT syndrome,', 'congestive heart failure, bradyarrhythmias, and drugs known to prolong the QT interval,', 'including Class Ia and III antiarrhythmics. Monitor and correct electrolyte abnormalities in all', 'patients as per the Trial Flow Sheet (Section 6.0). If QTc prolongation is noted, withhold drug', 'and resume at reduce dose of lenvatinib as per Table 3 (Dose Modifications for Lenvatinib', 'Treatment-Related Toxicity).', '5.2.2.2.4 Management of hepatotoxicity', 'The most commonly reported liver-related adverse reactions in patients treated with lenvatinib', 'are increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and serum', 'bilirubin. Liver-related adverse reactions were reported at a high frequency in lenvatinib-treated', 'Page 20', 'Version Date: 02/09/2020']\n\n###\n\n", "completion": "END"}